Relevant concepts to engineer antibody-based molecules for HIV cure
Sign up to read this post
Join Now
Dr. Ferrari, M.D., is Professor at Duke University in the Department of Surgery and Molecular Genetics and Microbiology. He is also affiliated faculty at the Duke Global Health Institute, Duke Human Vaccine Institute, and Honorary Professor at the University of Cape Town Department of Immunology. Dr. Ferrari has worked on testing samples from vaccine recipients for cytotoxic T lymphocyte (CTL) and antibody dependent cellular cytotoxic (ADCC) responses for the HIV Vaccine Trial Network (HVTN, the Comprehensive Antibody-Vaccine Immune Monitoring Consortium (CA-VIMC) and for the Primate AIDS Vaccine Evaluation Group (PAVEG). He is currently the Director of the Center for AIDS Research Immunology Core and Mentoring Committee. He was the first to characterize vaccine-induced cross-clade clade CD8 CTL responses; he also identified the anti-C1C2 epitope as the most recognized epitope by ADCC Ab responses in infected individuals.